Personalized and Customized Proteomics
A comprehensive and interdisciplinary proteomics core for high sensitivity, high resolution and high throughput proteomics with particular emphasis on in depth proteomic consultation, referral to the optimal proteomics facility and a strong focus on clinical sample analysis.
Located in the Harvard Institutes of Medicine at the Harvard Medical School Longwood Campus.
The Cancer Proteomics Core
A core facility of the Dana-Farber/Harvard Cancer Center.
The Core provides all of the tools of modern functional proteomics. The Cancer Proteomics Core offers the expertise and highly specialized proteomic and bioinformatic services as part of a comprehensive and highly personalized service that is unique within the Harvard Medical Community. Equipped with State-of-the-Art technologies for
- Protein profiling
- Protein identification
- Protein and peptide fractionation
- Personalized experimental design consultation
- Comprehensive individualized bioinformatics support.
Functional genomics and proteomics are at the forefront of cancer research and clinical investigation, both aiming to gain comprehensive understanding of the expression, modification, interaction, and regulation of genes and proteins in cells. As we emerge into the post-genome era, proteomics has evolved as the driving force to translate genomic information into understanding how the cell actually works and how disease processes operate. Proteomic technologies provide the means to define and compare protein profiles in normal and pathological samples, correlate protein profiles with biological activities, define disease mechanisms at a molecular level, establish interrelationships among proteins, identify temporal patterns of expression, and define the function of uncharacterized proteins. As a result, there is intense interest in applying proteomics to foster a better understanding of cancer processes, develop new biomarkers for diagnosis, early detection, prediction and prognosis of cancer, identify tumor antigens recognized by the immune system, discover new molecular targets for accelerated drug development and identify markers for therapeutic efficacy, toxicity and patient stratification leading ultimately to better management of cancer patients. Ideally, such a proteome framework would encompass knowledge of all human proteins, from amino acid sequences to post-translational modifications, to protein-protein interactions, cellular and subcellular distributions, and their temporal patterns of expression.
The Cancer Proteomics Core offers the expertise and highly specialized proteomic and bioinformatic services as part of a comprehensive and highly personalized service that is unique within the Harvard Medical Community. A number of biotech companies offering proteomic services have been established recently. However, their charges are inherently greater and without the consultative support provided by the DF/HCC Cancer Proteomics Core. As part of the proteomics core, we plan to implement a strong educational program to teach DF/HCC investigators about proteomic applications to cancer related research projects. Thus, the core will combine consultation, service and education into a comprehensive, translationally and clinically oriented proteomics core.